Atorva is the new product of Tchaikapharma with Marketing Authorisation.

Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Atorva 40 mg and 80 mg film-coated tablets. Each tablet contains the active substance atorvastatin as atorvastatin calcium.

Atorva is indicated:

– as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults, adolescents and children over the age of 10 with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) and combined (mixed) hyperlipidemia (corresponding to Fredrickson’s classification type IIa and IIb), when response to diet and other non-pharmacological methods is insufficient;

– for lowering total cholesterol and LDL-C in adult patients with homozygous familial hypercholesterolemia as an adjunct to other methods of decreasing the level of lipids (e.g. LDL Apheresis) or in cases where these methods are not available;

– for prevention of cardiovascular events in adult patients at high risk for a first cardiovascular event as an adjunct to correction of other risk factors.

Atorva is subject to medical prescription.

ATC code: C10AA 05